The INVEST Precision Medicine conference cast a spotlight on the role of children’s hospitals, biopharma companies, diagnostic companies and startups in biopharma innovation. The video recordings of the conference sessions are now available to view.
Panelists at MedCity INVEST Precision Medicine said startups can gain valuable expertise and experience through the process of seeking out non-dilutive funding.
On the final day of INVEST Precision Medicine, a panel with Caris Health, CVS Health, and Intermountain Healthcare will share assessments of precision medicine’s progress and the outlook for this sector. Also, a panel will highlight non dilutive funding opportunities for startups. Register now!
Shots: Regeneron will be responsible to deliver treatment doses for six years post-approval of product from the FDA, will receive compensation of ~$10M & average of $67M/year in 2021 and each for the next five years (2022-2026) respectively In 2019, the PALM trial evaluated REGN-EB3 vs ZMapp conducted in the Democratic Republic of the Congo, …
The contract covers manufacture and supply of the two-antibody drug cocktail REGN-COV2. The company had announced Monday that it entered the drug into three late-stage clinical studies, both as a treatment for existing SARS-CoV-2 infections and a preventive treatment for healthy exposed people.